US FDA sets PDUFA action dates for Bydureon and peginesatide

12 August 2011

US drugmakers Amylin Pharmaceuticals (Nasdaq: AMLN), Eli Lilly (NYSE: LLY) and Alkermes (Nasdaq: ALKS) said yesterday that the US Food and Drug Administration has acknowledged their resubmission of the New Drug Application for the type 2 diabetes drug candidate Bydureon (exenatide extended-release for injectable suspension), and has assigned a new Prescription Drug User Fee Act (PDUFA) action date of January 28, 2012.

Bydureon, the long-acting formulation of already-marketed Byetta, was recently approved in the European Union (The Pharma Letter June 22) but has so far been delayed in the USA with two complete response letters issued by the FDA in March and October last year, which called for additional clinical data. The companies’ goal had been to re-file the NDA with the required data by end-2011, so the latest move means they have beaten their targets have submitted this last month.

"If approved, we believe Bydureon will be an important new option for type 2 diabetes patients, as the first once-weekly treatment available in the USA," said Christian Weyer, senior vice president, R&D at Amylin, adding:. "We will continue to work with the FDA through this stage of the review process."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical